Seeking Alpha

A host of Wall Street firms weigh in on NuVasive (NUVA -34%), cutting their ratings after the...

A host of Wall Street firms weigh in on NuVasive (NUVA -34%), cutting their ratings after the company lowered its Q3 revenue outlook late yesterday. Barclay's downgrades the shares to Equalweight, JMP to Market Perform, First Analysis to Equal Weight, Summer Street to Neutral, BMO and RBC to Underperform, and Well Fargo to Market Perform. Wells also also hacked it's price target range on the shares to $15 - $16 from $29 - $31.

Check out Seeking Alpha’s new Earnings Center »

Comments (1)
  • anil92691
    , contributor
    Comments (414) | Send Message
     
    The influence that orthopedic reps have is amazing as we just saw see here. The sales reps have tight relationships with orthopedic surgeons to the point that they are unethical and will probable be illegal as the sunshine act gets enforced. Worse is the distribution companies that orthopedic surgeons have formed to make even more money over and above their usual medical practice and surgery centers.
    5 Oct 2012, 01:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs